Literature DB >> 24614566

Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency.

Alain Braillon1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24614566     DOI: 10.1136/bmj.g2017

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Authors' Reply to Alain Braillon's Comment on "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence".

Authors:  Julia M A Sinclair; Sophia E Chambers; David S Baldwin
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

2.  Comment on: "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence".

Authors:  Alain Braillon
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

3.  Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?

Authors:  Alain Braillon; Francoise Taiebi; Amal Bernoussi
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 4.  Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.

Authors:  Clément Palpacuer; Bruno Laviolle; Rémy Boussageon; Jean Michel Reymann; Eric Bellissant; Florian Naudet
Journal:  PLoS Med       Date:  2015-12-22       Impact factor: 11.069

5.  Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing?

Authors:  Alain Braillon; Bernard Granger
Journal:  Subst Abuse Rehabil       Date:  2015-06-29

6.  Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.

Authors:  Clément Palpacuer; Karima Hammas; Renan Duprez; Bruno Laviolle; John P A Ioannidis; Florian Naudet
Journal:  BMC Med       Date:  2019-09-16       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.